Association of Cystatin C and Bone Mineral Density in Diabetic Patients.
1 other identifier
observational
100
1 country
1
Brief Summary
Type 1 diabetes is associated with low bone mineral density(BMD) and type 2 diabetes with normal or high BMD. Cystatin C is a small molecule that is used to measure kidney function but it's not a troponin of the kidney. It has been associated with many other diseases like atrial fibrillation, depressive symptoms, melanoma, etc. This crossectional clinical study was done to evaluate the association between Cystatin C and Bone mineral density in both types of diabetic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 4, 2019
CompletedFirst Submitted
Initial submission to the registry
July 11, 2019
CompletedFirst Posted
Study publicly available on registry
July 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 25, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 25, 2019
CompletedJuly 15, 2019
July 1, 2019
6 months
July 11, 2019
July 12, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Serum Cystatin C
It is measured as a part of routine investigation at the time of admission
6 months
Secondary Outcomes (1)
Bone mineral density
6 months
Study Arms (1)
Diabetic adults
Interventions
Cystatin C is measured as a part of routine investigation at the time of admission.
Eligibility Criteria
Inpatient in the department of endocrinology and metabolism in the fifth affiliated hospital of Sun Yat-Sen University.
You may qualify if:
- Type 1 or type 2 diabetes male / female, older than 50 years old.
You may not qualify if:
- Use of any drug that affects bone metabolism (bisphosphonate, denosumab, teriparatide, steroids, anticancer drugs, thyroid hormones, antidepressants, antiretrovirals, calcium, vitamins A/D)
- Any disease affecting bone minerals (hyperthyroidism, hypothyroidism, parathyroid disease, Cushing's disease, rickets/osteomalacia, collagen disorders, rheumatoid arthritis)
- Kidney disease, urinary albumin-creatinine ratio greater than 30 mg / g or GFR \<60ml / min / 1.73m2.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ashish Shrestha
Zhuhai, Guangdong, 15000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiao Chun Shu
Fifth affiliated hospital of Sun Yat-Sen University
- PRINCIPAL INVESTIGATOR
Ashish Shrestha
Fifth affiliated hospital of Sun Yat-Sen University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician
Study Record Dates
First Submitted
July 11, 2019
First Posted
July 15, 2019
Study Start
July 4, 2019
Primary Completion
December 25, 2019
Study Completion
December 25, 2019
Last Updated
July 15, 2019
Record last verified: 2019-07
Data Sharing
- IPD Sharing
- Will not share